Abstract
Recombinant μ and δ opioid receptors expressed in cell lines can form heterodimers with distinctive properties and trafficking. However, a role for opioid receptor heterodimerization in neurons has yet to be identified. The inhibitory coupling of opioid receptors to voltage-dependent Ca2+ channels (VDCCs) is a relatively inefficient process and therefore provides a sensitive assay of altered opioid receptor function and expression. We examined μ-receptor coupling to VDCCs in dorsal root ganglion neurons of δ(+/+), δ(+/-), and δ(-/-) mice. Neurons deficient in δ receptors exhibited reduced inhibition of VDCCs by morphine and [d-Ala2,Phe4,Gly5-ol]-enkephalin (DAMGO). An absence of δ receptors caused reduced efficacy of DAMGO without affecting potency. An absence of δ receptors reduced neither the density of VDCCs nor their inhibition by either the GABAB receptor agonist baclofen or intracellular guanosine 5′-O-(3-thio)triphosphate. Flow cytometry revealed a reduction in μ-receptor surface expression in δ(-/-) neurons without altered DAMGO-induced internalization. There was no change in μ-receptor mRNA levels. d-Phe-Cys-Tyr-d-Trp-Arg-Thr-Pen-Thr-NH2-sensitive μ-receptor-coupling efficacy was fully restored to δ(+/+) levels in δ(-/-) neurons by expression of recombinant δ receptors. However, the dimerization-deficient δ-15 construct expressed in δ(-/-) neurons failed to fully restore the inhibitory coupling of μ receptors compared with that seen in δ(+/+) neurons, suggesting that, although not essential for μ-receptor function, μ-δ receptor dimerization contributes to full μ-agonist efficacy. Because DAMGO exhibited a similar potency in δ(+/+) and δ(-/-) neurons and caused similar levels of internalization, the role for heterodimerization is probably at the level of receptor biosynthesis.
Footnotes
-
This work was supported by the National Institutes of Health National Institute on Drug Abuse [Grants DA05010, DA00484].
-
ABBREVIATIONS: VDCC, voltage-dependent Ca2+ channel; DAMGO, [d-Ala2,Phe4,Gly5-ol]-enkephalin; DPDPE, [d-Pen2,Pen5]-enkephalin; CTAP, d-Phe-Cys-Tyr-d-Trp-Arg-Thr-Pen-Thr-NH2; GTPγS, guanosine 5′-O-(3-thio)triphosphate; DRG, dorsal root ganglion; CFP, δ-cerulean fluorescent protein; PBS, phosphate-buffered saline; APC, allophycocyanin; FI, fluorescence intensity; CT, count threshold; HEK, human embryonic kidney.
-
↵
The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
- Accepted April 8, 2009.
- Received March 2, 2009.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|